ML22334A046: Difference between revisions

From kanterella
Jump to navigation Jump to search
(StriderTol Bot insert)
 
(StriderTol Bot change)
 
(One intermediate revision by the same user not shown)
Line 24: Line 24:
==Purpose:==
==Purpose:==
Provide an opportunity to hear views from the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on medical-related topics of regulatory interest.
Provide an opportunity to hear views from the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on medical-related topics of regulatory interest.
Scheduled:         December 6, 2022 10:00 am Duration:           Approx. 2 hours Location:           Commissioners Conference Room, 1st fl OWFN
Scheduled:
December 6, 2022 10:00 am Duration:
Approx. 2 hours Location:
Commissioners Conference Room, 1st fl OWFN


==Participants:==
==Participants:==
Presentation ACMUI Panel                                                                 60 mins.*
Presentation ACMUI Panel 60 mins.*
Darlene Metter, M.D., ACMUI Chair Topic:
Darlene Metter, M.D., ACMUI Chair Topic:
* Overview of ACMUI activities Michael OHara, Ph.D., ACMUI Food and Drug Administration Representative Topic:
* Overview of ACMUI activities Michael OHara, Ph.D., ACMUI Food and Drug Administration Representative Topic:
Line 33: Line 36:
* Emerging Radiopharmaceuticals in an Expanding Nuclear Medicine Arena
* Emerging Radiopharmaceuticals in an Expanding Nuclear Medicine Arena
* Impacts of the American Board of Radiologys Request to Terminate NRC Recognition of the American Board of Radiologys Board Certification Processes Megan Shober, ACMUI Agreement States Representative Topic:
* Impacts of the American Board of Radiologys Request to Terminate NRC Recognition of the American Board of Radiologys Board Certification Processes Megan Shober, ACMUI Agreement States Representative Topic:
* ACMUIs Comments on the NRC Staffs Regulatory Basis for the Rulemaking on Emerging Medical Technologies and Rubidium-82 Generators
* ACMUIs Comments on the NRC Staffs Regulatory Basis for the Rulemaking on Emerging Medical Technologies and Rubidium-82 Generators  


Commissioners Q & A                                                   50 mins.
Commissioners Q & A 50 mins.
Discussion - Wrap-up                                                     5 mins.
Discussion - Wrap-up 5 mins.  
*For presentation only and does not include time for Commission Q & As}}
*For presentation only and does not include time for Commission Q & As}}

Latest revision as of 12:01, 27 November 2024

M221206: Agenda - Meeting with the Advisory Committee on the Medical Uses of Isotopes
ML22334A046
Person / Time
Issue date: 12/06/2022
From:
NRC/OCM
To:
Shared Package
ML22293A439 List:
References
M221206
Download: ML22334A046 (2)


Text

AGENDA

Title:

MEETING WITH THE ADVISORY COMMITTEE ON THE MEDICAL USES OF ISOTOPES (Public Meeting)

Purpose:

Provide an opportunity to hear views from the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on medical-related topics of regulatory interest.

Scheduled:

December 6, 2022 10:00 am Duration:

Approx. 2 hours2.314815e-5 days <br />5.555556e-4 hours <br />3.306878e-6 weeks <br />7.61e-7 months <br /> Location:

Commissioners Conference Room, 1st fl OWFN

Participants:

Presentation ACMUI Panel 60 mins.*

Darlene Metter, M.D., ACMUI Chair Topic:

  • Overview of ACMUI activities Michael OHara, Ph.D., ACMUI Food and Drug Administration Representative Topic:
  • ACMUIs Review of Yttrium-90 Medical Events Hossein Jadvar, M.D., Ph.D., ACMUI Nuclear Medicine Physician Topics:
  • Emerging Radiopharmaceuticals in an Expanding Nuclear Medicine Arena
  • Impacts of the American Board of Radiologys Request to Terminate NRC Recognition of the American Board of Radiologys Board Certification Processes Megan Shober, ACMUI Agreement States Representative Topic:
  • ACMUIs Comments on the NRC Staffs Regulatory Basis for the Rulemaking on Emerging Medical Technologies and Rubidium-82 Generators

Commissioners Q & A 50 mins.

Discussion - Wrap-up 5 mins.

  • For presentation only and does not include time for Commission Q & As